glp·helper
glphelper.com/semaglutide/texas/grapevine
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Grapevine, TX

Verified Semaglutide providers in Grapevine, TX. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
26
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Texas
27 of 27 shown

Find a Semaglutide provider in Texas.

Every entry is checked against the NPI registry and the Texas medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Texas city · /semaglutide/texas/{city}
§ 03Getting Semaglutide in Grapevine
27 providers · Grapevine, TX

How to get Semaglutide in Grapevine.

27 GLP-1 prescribers and 7 local resource types are on record for Grapevine, plus 3 nearby towns in the directory.

Prescribers in Grapevine
27 prescribers
27 GLP-1 prescribers in Grapevine, most listed as Family Medicine (13), Internal Medicine (12) and Internal Medicine, Endocrinology, Diabetes & Metabolism (1). Any Texas-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Southlake (26 providers), Coppell (28 providers) and Euless (30 providers).
Around the prescription in Grapevine
7 listed nearby
6 dietitians, 2 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Grapevine.
Medicaid (weight loss)
Diabetes only
As of April 2026, Texas Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Texas’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Grapevine

Grapevine, Texas has a population of 50,631 people. The adult obesity rate in Grapevine is an age-adjusted estimate of 28.8%, 6.8 percentage points below the Texas state rate of 35.6%. Diagnosed diabetes reaches 8.6% of adults in Grapevine. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 20.8% of adults in Grapevine.

of Grapevine adults have obesity
28.8%
diagnosed diabetes
8.6%
no regular physical activity
20.8%

Age-adjusted estimates for Grapevine, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losswhat happens after GLP-1s stop
§ 05Support around Semaglutide in Grapevine
6 fitness clubs

The prescription is one part. Here is the rest, in Grapevine.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Grapevine, TX, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

The REC of Grapevine
REC CENTER
4.7 on Google · 1048 reviews
1175 Municipal Way
Website
NRH Centre
REC CENTER
4.6 on Google · 839 reviews
6000 Hawk Ave
Website
The Keller Pointe
REC CENTER
4.3 on Google · 590 reviews
405 Rufe Snow Dr
Website
The CORE
REC CENTER
4.5 on Google · 489 reviews
234 Parkway Blvd
Website
Euless Family Life Center
REC CENTER
4.5 on Google · 420 reviews
300 W Midway Dr
Website
Northwest Park Recreation Center
REC CENTER
4.6 on Google · 401 reviews
2800 Cheyenne St
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Samira Amlani, RD LD
RD
Registered dietitian
3636 N Macarthur Blvd Ste 120
Call 469-565-2539NPI 1043567241
Vicki Bailey, MS, RD, LD
RD
Registered dietitian
1650 W College St
Call 817-424-4669NPI 1811521610
Melissa Brown, RD LD
RD
Registered dietitian
3800 Grapevine Mills Pkwy Apt 836
Call 318-558-1426NPI 1649515909
Brittney Carroll, MBA, RDN, LDN
RD
Registered dietitian
2451 W Grapevine Mills Cir # 1079
Call 469-444-0715NPI 1881570737
Megan Guynn, RDN
RD
Registered dietitian
3900 Grapevine Mills Pkwy Unit 3233
Call 425-358-1479NPI 1568133593
Rebecca Hansen-Quiggle, R.D
RD
Registered dietitian
1518 Overlook Dr
Call 817-524-8820NPI 1285981209
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Texas

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in Texas

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]